Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. - Wikidata - awgldk - TriplyDB

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

http://www.wikidata.org/entity/Q44053875

about

Pharmacotherapies for obesity: past, current, and future therapies Metformin for obesity or overweight Metformin for obesity or overweight 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor Who will lose weight? A reexamination of predictors of weight loss in women Gender-related Differences in Food Craving and Obesity Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives The New Era of Drug Therapy for Obesity: The Evidence and the Expectations Targeting central melanocortin receptors: a promising novel approach for treating alcohol abuse disorders Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date The pharmacological treatment and management of obesity.Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.Tackling obesity: new therapeutic agents for assisted weight loss.Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?Metformin as treatment for overweight and obese adults: a systematic review Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial Combinations of drugs in the Treatment of Obesity.Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?Sizing up pharmacotherapy for obesity An evolving scientific basis for the prevention and treatment of pediatric obesity Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment.The overlap between binge eating disorder and substance use disorders: Diagnosis and neurobiology.Emerging pharmacotherapy for obesity.Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study.Current and investigational antiobesity agents and obesity therapeutic treatment targets.The effect of antidepressants on lipid homeostasis: a cardiac safety concern?Weight gain, obesity, and psychotropic prescribing.Present and future: pharmacologic treatment of obesity Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options.Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice.Treatment options for obesity and potential therapies on the horizon Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.Advances in anti-obesity therapeutics.Anorexia nervosa and obesity are associated with opposite brain reward response HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in Rats Optimal diabetes management during medical weight loss for cardiovascular risk reduction.Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.Drug Insight: appetite suppressants.Food reinforcement and eating: a multilevel analysis.

P2860

Q21296814-86A60D98-3CC9-48B2-904A-3AE0A2BBA412 Q24195145-4F414DED-790D-47D1-83F8-B636D0F125E4 Q24236796-E9278B71-F550-4B52-809F-FED817827EA1 Q24530904-95354719-D63C-4B25-86E3-162134186F36 Q24563250-F9269D4F-F6E7-47F4-BD50-11C3013DE96A Q24799891-C8827270-F98E-4A72-830E-2B2946CC9804 Q26746183-31FF0D0E-E5ED-4084-8E70-948964AA484F Q26746239-FD3D3922-A92F-44E4-A082-56D8BF4A5E1C Q26827555-086B79FC-9AD7-4FD1-837B-DA9978AC0739 Q27008813-D2D65372-02E0-4DEE-A4B2-E707E3CD09ED Q27014110-5F1D0178-33B3-4F1D-9F10-BF2E6C3CF0A6 Q30399340-E9410F09-C465-4B96-8857-FCE68C79CA38 Q30400748-56E556FA-0D18-443C-BADE-0368ECFD32CD Q30401145-AF100C04-63D0-4700-870E-30F284906E4B Q30442979-3EA8FAD4-3337-40C8-BB78-A485B33A4E0C Q33224084-7D0291AA-B395-4230-8423-12B3BAF143F5 Q33615158-D55EE999-8084-4E3D-A387-E9A90693FE3A Q33664063-93EFBBBC-0B6A-4D95-AC16-7DE63D129E25 Q33890570-6B3796DB-A3FB-4A07-BEF7-96BF41E347A2 Q33969368-E6EA52FE-AFE9-460E-9FDA-4A29E6BFF890 Q34028763-A893CD0F-BF75-4F65-834C-E1AEBB99E693 Q34128192-D5510094-A4B6-4757-A8DD-C0A532B914AB Q34133292-459046CE-E326-4461-8EDF-5BDA894021C0 Q34207458-9E1F4F8B-C6E0-4D06-96BA-D73CAF77BA86 Q34217281-1FA4C037-8BCF-4FBA-A331-E5D5F512CFD4 Q34344786-496BF810-FC18-40C7-8A3C-D649D9E457A2 Q34538100-21472907-71A5-474B-8637-83459FCF8D30 Q34557537-1D182791-12B7-4D51-8169-1A47583BF7E1 Q34572487-1541E97C-B30E-487B-B699-EAC11714BDD5 Q35029802-B4CF0BDE-5297-4C7F-9E97-2A4BE100DAFD Q35096627-3243F1AE-E5DA-4B06-BB20-9F1AEB72F1C6 Q35111291-B8A9F2E5-42B0-487F-9C52-7B270B0D5591 Q35695148-99F7D4B1-683B-4CF9-9D06-E2A320B240D6 Q36099405-6EF3547C-7DEF-40B4-861D-BBB7187D81F9 Q36100291-BB46B75E-5D6B-4C92-BDC9-6EDD77CAD20B Q36176479-9C192AC6-F333-426F-97A4-408D1E34C130 Q36216869-CE0B5562-492C-44D3-9749-B5B3DFD01DD4 Q36219670-090B141B-8922-4933-8D34-A34028DCA25E Q36304086-7CF04F80-F1BE-4A05-B1D5-D469EE3CCAFE Q36416603-0AE1011E-F014-4671-A924-3F8D74983D80

P2860

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

http://www.wikidata.org/entity/Q44053875

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

@en

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

@nl

type

label

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

@en

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

@nl

prefLabel

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

@en

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

@nl

P1433

Q44053875-5CCFA782-1EA8-49E1-ABB8-1D784823D790

P1476

Q44053875-58C67CC4-F8E5-49BE-A326-73C23278F2CF

P2093

Q44053875-46EF38D4-B7D7-479A-A976-43BCFB4D7E75

Q44053875-4CED2EA6-9F1F-4CA8-87F7-4819C8E10B8E

Q44053875-5E9E51A6-1C8A-4D7D-853C-8AE211436129

Q44053875-80AB1613-B04F-49F2-A288-FFC6A244ADAA

Q44053875-B7405076-39E0-42C3-84A7-C538EDA97874

P2860

Q44053875-0D879202-D93B-4989-A70D-62C13E761FB1

Q44053875-335142DC-DEDB-478C-9A9F-BEF2EE64F5BB

Q44053875-368D386D-85E8-401F-92FD-DC9D952C727D

Q44053875-4585E8A7-5B21-4382-9BB1-65737D6023D0

Q44053875-5B35C8EA-3A7A-4A4A-A7B2-1F115834564C

Q44053875-84E195EF-AB7D-4BBF-9FB7-E9183246C8A1

Q44053875-87D79768-EF08-4E97-BC90-74E7B9CEE2DE

Q44053875-8898C4D1-9C90-4FEE-AF32-FED7745673F2

Q44053875-94D81E29-080C-4C3C-A42A-F2DC959BBA02

Q44053875-C843E4BB-70EF-4DC9-9EC8-6A096A7C9789

P304

Q44053875-B298A57B-65F7-4ED2-86A7-B91D3F934C9B

P31

Q44053875-B7C6D291-C84E-45D6-9DBD-07C5DFA36D4A

P356

Q44053875-954CFD25-24DC-4A4D-955A-B48C0AD4A7F4

P433

Q44053875-22780CE5-590E-417F-A5DA-19788A3A7204

P478

Q44053875-4B651037-C2EE-4D3A-B5D3-39EFBCAFEEFF

P50

Q44053875-889A610A-5598-4FB8-B881-8E3D558F79E1

P577

Q44053875-1CA480B4-302C-4C0B-9CEC-2BACE9473D6D

P5875

Q44053875-2C0182C4-30FF-4581-A8E0-916B8E81D9AC

P698

Q44053875-A57C5C42-DF4D-40E4-9A4D-F967A35A20A6

P921

Q44053875-B40824C6-69EB-4E3D-A76F-5868B78D0F6C

P356

P1433

P1476

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial

@en

P2093

Frank L Greenway

http://www.w3.org/2001/XMLSchema#string

James McKenney

http://www.w3.org/2001/XMLSchema#string

James W Anderson

http://www.w3.org/2001/XMLSchema#string

Ken Fujioka

http://www.w3.org/2001/XMLSchema#string

Kishore M Gadde

http://www.w3.org/2001/XMLSchema#string

P2860

Annual Deaths Attributable to Obesity in the United States

Brain dopamine and obesity.

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

The role of exercise in the treatment of obesity.

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Safety profile of sustained-release bupropion in depression: results of three clinical trials.

Weight control in the physician's office.

Successful long-term maintenance of substantial weight loss: one program's experience.

Long-term weight control with meal replacements.

Five-year self-management of weight using meal replacements: comparison with matched controls in rural Wisconsin.

P304

633-641

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/OBY.2002.86

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Patrick M O'Neil

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11273092

http://www.w3.org/2001/XMLSchema#string

P698

12105285

http://www.w3.org/2001/XMLSchema#string

P921